Drug intelligence / Profile preview

pb-1902

Development stage: Unknown
Lead developer: PegBio
Modality: Small Molecules
Administration: Oral

Overview

PB-1902 is an investigational drug under development for the treatment of opioid-induced constipation (OIC). It is administered orally and acts by targeting the mu-opioid receptor. The drug is currently in Phase I clinical trials, developed by PegBio, a biopharmaceutical company specializing in PEGylation technology and PEG synthesis[1][2][5].

Targets

MOR (Mu opioid receptor)

Beyond the preview

Go deeper on pb-1902.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pb-1902.

Explore the full profile